Results 11 to 20 of about 61,538 (280)

Guidelines of the International Headache Society for Controlled Clinical Trials in Idiopathic Intracranial Hypertension [PDF]

open access: yesCephalalgia, 2023
The quality of clinical trials is essential to advance treatment, inform regulatory decisions and meta-analysis. With the increased incidence of idiopathic intracranial hypertension and the emergence of clinical trials for novel therapies in this ...
S. Mollan   +15 more
semanticscholar   +3 more sources

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial [PDF]

open access: yesBrain : a journal of neurology, 2023
Therapeutics to reduce intracranial pressure are an unmet need. Preclinical data have demonstrated a novel strategy to lower intracranial pressure using glucagon-like peptide-1 (GLP-1) receptor signalling.
J. Mitchell   +11 more
semanticscholar   +3 more sources

Optic Nerve Ultrasound Evaluation in Idiopathic Intracranial Hypertension

open access: yesFrontiers in Medicine, 2022
Idiopathic intracranial hypertension (IIH) is a disease with a heterogeneity of possible causes, which needs to be quickly diagnosed. Ocular ultrasonography could be considered a useful tool to diagnose this condition in a fast and non-invasive way.
Maddalena De Bernardo   +5 more
doaj   +2 more sources

Rapid Recovery of Visual Acuity after Lumboperitoneal Shunt Operation in Malignant Idiopathic Intracranial Hypertension [PDF]

open access: yesCase Reports in Ophthalmological Medicine, 2011
Background. Idiopathic intracranial hypertension can cause rapid deterioration of visual acuity in some severe cases, and these cases are usually thought to have “malignant” form of this disease. Case.
Levent Sinan Bir   +4 more
doaj   +4 more sources

Addison's disease presenting with idiopathic intracranial hypertension in 24-year-old woman: a case report [PDF]

open access: yesJournal of Medical Case Reports, 2010
Introduction Idiopathic intracranial hypertension can rarely be associated with an underlying endocrine disorder such as Cushing's syndrome, hyperthyroidism, or with administration of thyroxine or growth hormone.
Moore Peter   +3 more
doaj   +5 more sources

Is the adjustable lumbo-peritoneal shunt a valid option for managing symptomatic idiopathic intracranial hypertension? A case report of a multidisciplinary management [PDF]

open access: yesInterdisciplinary Neurosurgery, 2019
Background: Idiopathic intracranial hypertension is a rare disorder, characterized by raised intracranial pressure with no recognizable cause. Headache, decreased visual acuity and papilledema are the main clinical manifestations.
Umberto A. Arcidiacono, M.D.   +3 more
doaj   +3 more sources

Idiopathic intracranial hypertension as a presenting sign of adrenal insufficiency [PDF]

open access: yesSAGE Open Medical Case Reports, 2018
Idiopathic intracranial hypertension is a diagnosis of exclusion defined by elevated intracranial pressure without mass lesions or hydrocephalus.
Sandra Shenouda   +3 more
doaj   +3 more sources

Cluster-like headache and idiopathic intracranial hypertension: a case report [PDF]

open access: hybrid, 2008
Cluster headache (CH) is a well-defined primary headache syndrome, but cases of symptomatic headache with clinical features of CH have been previously reported.
Lucia Testa   +4 more
openalex   +3 more sources

Diagnosis of idiopathic intracranial hypertension: A proposal for evidence-based diagnostic criteria

open access: yesCephalalgia, 2023
Background Based on expert opinion, abducens nerve palsy and a neuroimaging criterion (≥3 neuroimaging signs suggestive of elevated intracranial pressure) were added to the diagnostic criteria for idiopathic intracranial hypertension.
J. J. Korsbæk   +5 more
semanticscholar   +1 more source

Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension

open access: yesThe Journal of Headache and Pain, 2023
Background In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option.
Nik Krajnc   +9 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy